Tracers / [161Tb]Tb-BPAMD
[161Tb]Tb-BPAMD
Also written as [Tb-161]Tb-BPAMD
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated bisphosphonate
- Target / mechanism
- Hydroxyapatite binding at sites of bone remodeling (bone-seeking bisphosphonate) PMID 41900797
- Clinical application
- Targeted radionuclide therapy of bone metastases PMID 41900797
- Theranostic pair
- <a href="/tracers/ga68-bpamd/">ga68-bpamd</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >98% | >97% at 48 h | BPAMD ABX | 41900797 2026 Pharmaceutics A solution of 100 µg BPAMD in 0.5 mL acetate buffer (0.4 M, pH 4.5) was mixed with 74 MBq of 161TbCl3 and heated at 95 °C for 30 min in a sealed vial. — Both complexes achieved a radiochemical yield of greater than 98%. |
Need this precursor?We can point you to suppliers for [161Tb]Tb-BPAMD, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68.